GLP-1 receptor agonists activate cellular pathways that enhance mitochondrial renewal and quality control, but whether these effects operate through direct receptor signaling or secondary metabolic changes remains unresolved. The evidence supports cardiovascular benefit in obesity, yet no clinical trial has yet measured mitochondrial endpoints directly in humans, limiting claims about whether GLP-1 agents modify aging itself.
Key Points
- GLP-1 RAs engage AMPK-PGC-1α signaling to promote mitochondrial biogenesis and repair
- Tissue-specific responses mean effects vary by organ; not uniformly receptor-dependent
- Clinical cardiovascular benefit documented, but direct mitochondrial endpoints unmeasured in humans
Longevity Analysis
Mitochondrial dysfunction underpins multiple age-related diseases—metabolic, cardiac, muscular, and neurological. GLP-1 agents show promise in restoring mitochondrial capacity and resilience, yet the mechanism remains unclear: whether the benefit flows from direct receptor activation in mitochondria-rich tissues or emerges secondarily from weight reduction and improved metabolic signaling. A rigorous research agenda that includes direct measurement of mitochondrial function across tissues and life stages is essential before positioning these agents as aging interventions. Current evidence supports their use for cardiometabolic disease, but claims of geroprotection outpace the data.
Original published by Wiley Aging Cell, by Renin Chang, Andy P. Tsai, Boyang Wang, Chia‐Jung Li .